Mark Fineman - Concepedia

Author

Mark Fineman

Amplyx Pharmaceuticals (United States)ORCID

Also Known As

B. Oguzhan, K. Gorbenko, Kim, Terri, M FINEMAN, M Fineman, M. B. Damholt, M. Fineman, M. S. Fineman, M.S. Fineman, MARK FINEMAN

Publications

11.2K

Citations

H-Index

Concepts

All Affiliations

Amplyx Pharmaceuticals (United States)Eli Lilly (United States)MedStar Health University of California San Diego University of North Carolina at Chapel Hill

About

Mark Fineman is an author at Amplyx Pharmaceuticals (United States) specializing in medicine, pharmacology, and diabetes.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	1.4K
2	Health Sciences	3	3	293
3	Social Sciences	1	1	72
4	Applied Physiology	1	1	26
5	Biochemistry	1	1	12

Mark Fineman

Publications

10.7K

Citations

H-Index

Page 1

	Year	Citations
Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes Ralph A. DeFronzo, Robert E. Ratner, Jenny Han, Diabetes Care	2005	1.5K
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes John B. Buse, Robert R. Henry, Jenny Han, Diabetes Care	2004	1.3K
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea David M. Kendall, Matthew C. Riddle, Julio Rosenstock, Diabetes Care	2005	1.2K
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study John B. Buse, Michael A. Nauck, Thomas Först, The Lancet Diabetes ManagementDiabetesType 2PharmacotherapyDiabetes Mellitus	2012	559
Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes Orville Kolterman, John B. Buse, Mark Fineman, The Journal of Clinical Endocrinology & Metabolism	2003	551
Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes Dennis Kim, Leigh MacConell, Dongliang Zhuang, Diabetes Care	2007	445
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus Orville Kolterman, Dennis Dong Hwan Kim, Larry Z. Shen, American Journal of Health-System Pharmacy	2005	434
Effect on Glycemic Control of Exenatide (Synthetic Exendin-4) Additive to Existing Metformin and/or Sulfonylurea Treatment in Patients With Type 2 Diabetes Mark Fineman, Thomas A. Bicsak, Larry Z. Shen, Diabetes Care	2003	355
The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies John B. Buse, Ralph A. DeFronzo, Julio Rosenstock, Diabetes Care	2015	320
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trial Robert E. Ratner, Richard A. Dickey, Mark Fineman, Diabetic Medicine	2004	303

Page 1